Merck says experimental skin disease drug meets main goal in mid-stage study

Merck NYSE:MRK said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps, abscesses and scarring.